NEW YORK, Aug. 19 - As big pharma's product pipeline continues to wither, the role of genomics-tool and -data providers becomes increasingly uncertain.

Will the pressure on pharma firms to develop new products at all costs mean that genomic companies can expect an increase in new-technology orders? Or will pharma's revenue woes mean that increased spending on new technology becomes foolish?


To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.